Is it not time to reveal the secret sauce of nicotine addiction?

K Michael Cummings

In the courtroom, cigarette companies like to paint a picture that their consumers are informed about the health risks of their products so that they can argue that smokers are fully responsible for any health consequences that might arise. While that is a convenient legal defense, it is a smoke screen. The reality is most consumers have not got a clue how their cigarettes are engineered and how the design of their cigarettes might relate to why they find it hard to stop smoking and why they get sick as a result. While I have heard defense lawyers argue that consumers really are not interested in knowing how their cigarettes are made, that argument is contradicted by polling data showing that the vast majority of smokers want to know more about the products they use.

While some governments have succeeded in requiring tobacco manufacturers to disclose information about their products, most of the data obtained has been useless to consumers, because it cannot be shared on the grounds that the design specifications are trade secrets. The paper by Velicer et al is important since it reveals that the trade secret argument used by manufacturers to keep consumers in the dark about how their products are engineered is baseless—because their own business records show that companies have for decades routinely analysed their competitors’ cigarettes in great detail. Thus, the information is neither secret nor commercially valuable, and thus does not meet the legal definition of a ‘trade secret’.

So why have cigarette manufacturers fought so hard to keep their historical brand formulas a secret? The answer can be found in the internal business records of the cigarette companies. In 1963, the chief lawyer for Brown & Williamson wrote—“we are in the business of selling nicotine, an addictive drug.” In a related business record written in the same year, the head scientist at Brown & Williamson observed: “the nicotine levels of B&W cigarettes were not obtained by accident… we can regulate fairly precisely the nicotine and sugar levels to almost any desired level management might require.” A 1972 RJ Reynolds Tobacco Company research and Development document observed that the company should “recognise the key role of nicotine in consumer satisfaction and promote our product with this in mind.” A similar focus can be found in a 1977 Philip Morris internal
business record which said that research into human smoking behaviour was performed to “increase corporate profits... and without the chemical compound (ie, nicotine) the cigarette market would collapse, PM would collapse, and we’d all lose our jobs and our consulting fees”.

No doubt consumers would be shocked to learn how cigarettes have been engineered with man-made tobaccos laced with ammonia, additives and other ingredients that changed frequently over time without notification and with little regard given to downstream health consequences (human experimentation without consent). However, another reason for keeping historical brand formulas secret can be found in a 1980 internal business record which revealed that inside the cigarette industry, lawyers warned that “the entire matter of addiction is the most potent weapon a prosecuting attorney can have in a lung cancer/cigarette case. We can’t defend continued smoking as free choice if the person was addicted”. 

The scientific consensus today is that nicotine addiction is the fundamental reason that people persist in smoking, which in turn results in one in two long-term cigarette smokers dying prematurely from smoking-related diseases. Were it not for designing products that induce and maintain nicotine addiction, we would not have a tobacco and health problem.

Given the emerging consensus that cigarettes have become even more dangerous and perhaps even more addictive over time (ie, the relative risks for smoking and multiple diseases have increased) there is an urgency to know why. Changes in product designs would seem to be a logical explanation, but without knowing precisely how different brands and sub-brands have been engineered and modified, it is impossible to know for sure.

One would never undertake a study to evaluate the health impact of a drug without knowing the precise specifications of the drug and ensuring its uniformity over the course of the study. Yet, that is precisely the problem that has confronted those evaluating the disease effects of cigarette smoking. Velicer et al are absolutely correct in pointing out the insanity of hiding behind trade secrets as an excuse not to release historical brand formulas.

Consumers and regulators have been kept in the dark for too long. Consumers cannot make informed product choices if product information is concealed; scientists cannot accurately assess the risks of a product if the product is being modified without their knowledge, and regulators like the Food and Drug Administration (FDA) cannot regulate a moving target. It is long since time to put the interests of consumers before those of cigarette manufacturers and require them to publicly disclose historical by-brand formulas and design specifications.

Competing interests KMC has received payment as an expert witness in litigation filed against the tobacco industry.

Provenance and peer review Commissioned; internally peer reviewed.

To cite Cummings KM. Tob Control 2015;24:420–421.

REFERENCES


Is it not time to reveal the secret sauce of nicotine addiction?

K Michael Cummings

_Tob Control_ 2015 24: 420-421
doi: 10.1136/tobaccocontrol-2015-052631

Updated information and services can be found at:
http://tobaccocontrol.bmj.com/content/24/5/420

These include:

**References**
This article cites 6 articles, 1 of which you can access for free at:
http://tobaccocontrol.bmj.com/content/24/5/420#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/